Floatz Rating
D30/100
Confidence
Indicative
Sponsor
University of Pennsylvania
Modality
protein_peptide
Development Phase
N/A
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
15Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT01851694CT.gov Beta-cell Response to Incretin Hormones in Cystic Fibrosis | — | Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Exocrine Pancreatic Insufficiency
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Gip (this asset) | University of Pennsylvania | N/A | D · 30 |
| Liprotamase | Anthera Pharmaceuticals | P4 | A |
| Pancrelipase | Anagram Therapeutics, Inc. | P4 | A |
| Panzytrat | Forest Laboratories | P4 | BB |
| Porcine Pert | Entero Therapeutics | P3 | BB |
| Triheptadecanoin | Children's Hospital of Philadelphia | P4 | BB |
| Adrulipase Alfa | Entero Therapeutics | P2 | BB |
| ang003 | Anagram Therapeutics, Inc. | P2 | B |
| Omeprazole | Children's Hospital of Philadelphia | P2 | B |
+15 more in the Exocrine Pancreatic Insufficiency cohort
Other indications for Gip
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Fatty Liver Disease | — | P1/2 | CCC · 48 |
| Type 2 Diabetes Mellitus | — | P1 | CCC · 48 |
| Metabolic Dysfunction-Associated Steatohepatitis | — | P1/2 | CC · 47 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Gip in Exocrine Pancreatic Insufficiency. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/gip-exocrine-pancreatic-insufficiency
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →